Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer

Breast Cancer Research and Treatment

Volumn 136, Issue 3, 2012, Pages 647-658

  Rocha, Ana ^a   Wang, Lei ^a   Penichet, Manuel ^b   Martins Green, Manuela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion; Chemotaxis; Cytokines; Gene expression; Migration

Indexed keywords

ELLAGIC ACID; LUTEOLIN; PLANT MEDICINAL PRODUCT; PUNICIC ACID; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHEMOKINE; CXCL12 PROTEIN, HUMAN; CYTOKINE; ESTROGEN RECEPTOR; LINOLENIC ACID; PROGESTERONE RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; METASTASIS; POMEGRANATE JUICE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; BEVERAGE; BREAST TUMOR; CELL MOTION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETICS; LYTHRACEAE; METABOLISM; MIGRATION INHIBITION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BEVERAGES; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; CELL MOVEMENT; CHEMOKINE CXCL12; CHEMOKINES; CYTOKINES; DRUG SCREENING ASSAYS, ANTITUMOR; ELLAGIC ACID; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LINOLENIC ACIDS; LUTEOLIN; PUNICACEAE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84876585707     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2264-5     Document Type: Article

References (51)

1. World Health Organization Facts and Figures. http://www.who.int. Accessed July 2012
2. Maughan KL, Lutterbie MA, Ham PS (2010) Treatment of breast cancer. Am Fam Physician 81:1339-1346
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62:10-29
4. Cazzaniga M, Bonanni B (2012) Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012:985620
5. Longtin R (2003) The pomegranate: nature's power fruit? J Natl Cancer Inst 95:346-348
6. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA (2000) Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 48:4581-4589
7. Kim ND, Mehta R, Yu W, Neeman I, Livney T, et al. (2002) Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71:203-217
8. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R, Ramachandran C, Rabi T, Kaplan B, Lansky E (2002) Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71(3):203-217
9. Dikmen M, Ozturk N, Ozturk Y (2011) The antioxidant potency of Punica granatum L. fruit peel reduces cell proliferation and induces apoptosis on breast cancer. J Med Food 12:1638-1646
10. Ozbay T, Nahta R (2011) Delphinidin inhibits HER2 and Erk1/2 signaling and suppresses growth of HER2-overexpressing and triple negative breast cancer cell lines. Breast Cancer 5:143-154
11. Dai Z, Nair V, Khan M, Ciolino HP (2010) Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in vitro. Oncol Rep 24(4):1087-1091
12. Wang LM, Xie KP, Huo HN, Shang F, Zou W, Xie MJ (2012) Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells. Asian Pac J Cancer Prev 13(4):1431-1437
13. Kim MJ, Woo JS, Kwon CH, Kim JH, Kim YK, Kim KH (2012) Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines. Cell Biol Int 36(4):339-344
14. Adams LS, Zhang Y, Seeram NP, Heber D, Chen S (2010) Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res 3(1):108-113
15. Grossmann ME, Mizuno NK, Schuster T, Cleary MP (2010) Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation. Int J Oncol 36:421-426
16. El Kar C, Ferchichi A, Attia F, Bouajila J (2011) Pomegranate (Punica granatum) juices: chemical composition, micronutrient cations, and antioxidant capacity. J Food Sci 76:C795-C800
17. Wang L, Alcon A, Yuan H, Ho J, Li QJ, Martins-Green M (2011) Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effects on prostate cancer cells. Integr Biol 3:742-754
18. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17(8):2074-2080
19. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, Harris NM, Neeman I, Campbell MJ (2005) Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel (TM). Invest New Drugs 23:11-20
20. Wang L, Ho J, Glackin C, Martins-Green M (2012) Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol 5:344-355
21. Roland CL, Harken AH, Sarr MG, Barnett CC Jr (2007) ICAM-1 expression determines malignant potential of cancer. Surgery 141(6):705-707
22. Nakagawa S, Miyoshi N, Ishii H, Mimori K, Tanaka F, Sekimoto M, Doki Y, Mori M (2011) Expression of CLDN1 in colorectal cancer: a novel marker for prognosis. Int J Oncol 39:791-796
23. Aderem A (1992) The MARCKS brothers: a family of protein kinase C substrates. Cell 71:713-716
24. Arbuzova A, Schmitz AAP, Vergeres G (2002) Cross-talk unfolded: MARCKS proteins. Biochem J 362:1-12
25. Sohr S, Engeland K (2008) RHAMM is differentially expressed in the cell cycle and down-regulated by the tumor suppressor p53. Cell Cycle 7:3448-3460
26. Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, Esguerra KV, Telmer PG, Luyt LG, Harrison R, McCarthy JB, Turley EA (2010) RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 285:26461-26474
27. Hatano H, Shigeishi H, Kudo Y, Higashikawa K, Tobiume K, Takata T, Kamata N (2011) RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR. Lab Invest 91:379-391
28. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14(17):5555-5564
29. Song L, Rape M (2010) Regulated degradation of spindle assembly factors by the anaphase-promoting complex. Mol Cell 38:369-382
30. Ohtsuka T, Nakanishi H, Ikeda W, Satoh A, Momose Y, Nishioka H, Takai Y (1998) Nexilin: a novel actin filament-binding protein localized at cellmatrix adherens junction. J Cell Biol 143:1227-1238
31. Yang C, Kazanietz MZ (2007) Chimaerins: GAPs that bridge diacylglycerol signaling and the small G-protein Rac. Biochem J 403:1-12
32. Caldon CE, Musgrove EA (2010) Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 17(5):2
33. Gorin MA, Pan Q (2009) Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Mol Cancer 8:9
34. Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16(11):2927-2931
35. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279
36. Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8:629-642
37. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198:11-26
38. Oyama T, Maluf H, Koerner F (1999) Atypical cystic lobules: an early stage in the formation of low-grade ductal carcinoma in situ. Virchows Arch 435:413-421
39. Oyama T, Iijima K, Takei H, et al. (2000) Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in situ. Breast Cancer 7:326-331
40. Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11(6):479-497
41. Dranoff Glenn (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11-22
42. Bonecchi R, Locati M, Mantovani A (2011) Chemokines and cancer: a fatal attraction. Cancer Cell 19(4):434-435
43. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Dinney CPN (2000) Interleukin 8 expression regulates tumorigenecity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119
44. Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2:375-391
45. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67(14):6854-6862
46. Ahmed OI, Adel AM, Diab DR, Gobran NS (2006) Prognostic value of serum level of inter-leukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol 13(2):61-68
47. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267:271-285
48. Fredriksson L, Li H, Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197-204
49. Song N, Huang Y, Shi H, Yuan S, Ding Y, Song X, Fu Y, Luo Y (2009) Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res 69:6057-6064
50. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A (2010) Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 224:39-44
51. Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, Fatatis A (2011) The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res 13:R91